{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:21:03Z","timestamp":1771950063857,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Reporting and analysis of Adverse Events Following Immunization (AEFIs) are the cornerstones of vaccine safety surveillance prompting causality assessment and signal detection. This paper describes the impact of the Italian Pharmacovigilance System of vaccines over a 10-year period (2008\u20132017). The reporting rate (RR) per all distributed dose was calculated. Serious AEFIs and causality assessments for fatal cases were described. The main results from signal detection were reported. During the study period, 46,430 AEFIs were reported with an overall RR of 17.2 per 100,000 distributed doses. Italy showed the highest number of reports among European countries. Only 4.4% of the reports came from citizens. Of the total, 12.7% were classified as serious with a RR over the study period of 2.20 per 100,000 distributed doses. They were mainly related to hyperpyrexia and usually had a positive outcome. Fatal outcomes were reported in 0.3% of the cases and were primarily associated with the influenza vaccine in elderly patients. None of these outcomes had a consistent causal association with the vaccination. Febrile convulsions by the measles, mumps, rubella and varicella vaccines and intussusception by the rotavirus vaccine were among the highlighted signals. The reporting rate and the analysis of serious events from 10\u00a0years support the good risk\/benefit profiles of vaccines.<\/jats:p>","DOI":"10.1038\/s41598-020-70996-x","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T10:04:26Z","timestamp":1598263466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ten years of vaccinovigilance in Italy: an overview of the pharmacovigilance data from 2008 to 2017"],"prefix":"10.1038","volume":"10","author":[{"given":"F.","family":"Moretti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gonella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gironi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. R.","family":"Marra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Santuccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Felicetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Petronzelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Marchione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. A.","family":"Barnaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Poli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Zanoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5108-5807","authenticated-orcid":false,"given":"U.","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,24]]},"reference":[{"key":"70996_CR1","unstructured":"WHO: Ten years in public health, 2007\u20132017. Report by Dr Margaret Chan, Director-General, World Health Organization. https:\/\/www.who.int\/publications\/10-year-review\/en\/ (2017)."},{"key":"70996_CR2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jpeds.2016.06.006","volume":"175","author":"ED McIntosh","year":"2016","unstructured":"McIntosh, E. D., Janda, J., Ehrich, J. H., Pettoello-Mantovani, M. & Somekh, E. Vaccine hesitancy and refusal. J. Pediatr. 175, 248\u2013249 (2016).","journal-title":"J. Pediatr."},{"key":"70996_CR3","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.vaccine.2017.12.074","volume":"36","author":"C Giambi","year":"2018","unstructured":"Giambi, C. et al. Parental vaccine hesitancy in Italy\u2014results from a national survey. Vaccine 36, 779\u2013787 (2018).","journal-title":"Vaccine"},{"key":"70996_CR4","first-page":"145","volume":"46","author":"C My","year":"2017","unstructured":"My, C., Danchin, M., Willaby, H. W., Pemberton, S. & Leask, J. Parental attitudes, beliefs, behaviours and concerns towards childhood vaccinations in Australia: a national online survey. Aust. Fam. Phys. 46, 145\u2013151 (2017).","journal-title":"Aust. Fam. Phys."},{"key":"70996_CR5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1517\/14740338.2016.1167869","volume":"15","author":"N Principi","year":"2016","unstructured":"Principi, N. & Esposito, S. Adverse events following immunization: real causality and myths. Expert Opin. Drug Saf. 15, 825\u2013835 (2016).","journal-title":"Expert Opin. Drug Saf."},{"key":"70996_CR6","doi-asserted-by":"crossref","first-page":"6672","DOI":"10.1016\/j.vaccine.2016.10.039","volume":"34","author":"A Di Pasquale","year":"2016","unstructured":"Di Pasquale, A. et al. Vaccine safety evaluation: practical aspects in assessing benefits and risks. Vaccine 34, 6672\u20136680 (2016).","journal-title":"Vaccine"},{"key":"70996_CR7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/QCO.0b013e328352f727","volume":"25","author":"H Rashid","year":"2012","unstructured":"Rashid, H., Khandaker, G. & Booy, R. Vaccination and herd immunity: what more do we know?. Curr. Opin. Infect Dis. 25, 243\u2013249 (2012).","journal-title":"Curr. Opin. Infect Dis."},{"key":"70996_CR8","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1016\/j.vaccine.2015.06.064","volume":"33","author":"SL Pollard","year":"2015","unstructured":"Pollard, S. L. et al. Estimating the herd immunity effect of rotavirus vaccine. Vaccine 33, 3795\u20133800 (2015).","journal-title":"Vaccine"},{"key":"70996_CR9","unstructured":"European Centre for Disease Prevention and Control (ECDC). Monthly measles and rubella monitoring report, January 2019. Stockholm: ECDC. https:\/\/ecdc.europa.eu\/sites\/portal\/files\/documents\/measles-rubella-monthly-surveillance-report-january-2019.pdf (2019)."},{"key":"70996_CR10","doi-asserted-by":"crossref","unstructured":"D\u2019Ancona F, et al. Introduction of new and reinforcement of existing compulsory vaccinations in Italy: first evaluation of the impact on vaccination coverage in 2017. Euro Surveill. Preprint at: https:\/\/www.igienistionline.it\/docs\/2018\/19eurosurveillance.pdf (2018).","DOI":"10.2807\/1560-7917.ES.2018.23.22.1800238"},{"key":"70996_CR11","doi-asserted-by":"crossref","unstructured":"Karafillakis E, Larson HJ; ADVANCE consortium. The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations. Vaccine. 35, 4840\u20134850 (2017).","DOI":"10.1016\/j.vaccine.2017.07.061"},{"key":"70996_CR12","unstructured":"European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP) Product- or Population-Specific Considerations I: Vaccines for prophylaxis against infectious diseases.https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/12\/WC500157839.pdf (2013)."},{"key":"70996_CR13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1539-6924.1988.tb01168.x","volume":"8","author":"RE Kasperson","year":"1988","unstructured":"Kasperson, R. E. et al. The social amplification of risk: a conceptual framework. Risk Anal. 8, 177\u2013187 (1988).","journal-title":"Risk Anal."},{"key":"70996_CR14","unstructured":"EU Regulation No 1235\/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726\/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394\/2007 on advanced therapy medicinal products. https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol1\/reg_2010_1235\/reg_2010_1235_en.pdf (2010)."},{"key":"70996_CR15","unstructured":"EU Directive No 2010\/84\/ of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001\/83\/EC on the Community code relating to medicinal products for human use. https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol1\/dir_2010_84\/dir_2010_84_en.pdf (2010)"},{"key":"70996_CR16","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1016\/j.vaccine.2009.01.059","volume":"27","author":"G Zanoni","year":"2009","unstructured":"Zanoni, G. et al. Vaccine adverse event monitoring systems across the European Union countries: time for unifying efforts. Vaccine 27, 3376\u20133384 (2009).","journal-title":"Vaccine"},{"key":"70996_CR17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.phrs.2014.10.011","volume":"92","author":"C Santuccio","year":"2015","unstructured":"Santuccio, C., Trotta, F. & Felicetti, P. Ongoing pharmacovigilance on vaccines. Pharmacol. Res. 92, 2\u20135 (2015).","journal-title":"Pharmacol. Res."},{"key":"70996_CR18","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.4161\/hv.34369","volume":"10","author":"HJ Clothier","year":"2014","unstructured":"Clothier, H. J. et al. Consumer reporting of adverse events following immunization. Hum. Vaccin. Immunother. 10, 3726\u20133730 (2014).","journal-title":"Hum. Vaccin. Immunother."},{"key":"70996_CR19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1128\/CVI.00541-12","volume":"20","author":"Y Hu","year":"2013","unstructured":"Hu, Y. et al. Surveillance for adverse events following immunization from 2008 to 2011 in Zhejiang Province, China. Clin. Vaccine Immunol. 20, 211\u2013217 (2013).","journal-title":"Clin. Vaccine Immunol."},{"key":"70996_CR20","doi-asserted-by":"crossref","first-page":"474","DOI":"10.26719\/2010.16.5.474","volume":"16","author":"S Al Awaidy","year":"2010","unstructured":"Al Awaidy, S., Bawikar, S., Prakash, K. R., Al Rawahi, B. & Mohammed, A. J. Surveillance of adverse events following immunization: 10 years\u2019 experience in Oman. East Mediterr. Health J. 16, 474\u2013480 (2010).","journal-title":"East Mediterr. Health J."},{"key":"70996_CR21","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1016\/j.vaccine.2010.04.002","volume":"28","author":"Z Schumacher","year":"2010","unstructured":"Schumacher, Z., Bourquin, C. & Heininger, U. Surveillance for adverse events following immunization (AEFI) in Switzerland 1991\u20132001. Vaccine 28, 4059\u20134064 (2010).","journal-title":"Vaccine"},{"key":"70996_CR22","first-page":"1","volume":"52","author":"W Zhou","year":"2003","unstructured":"Zhou, W. et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)\u2014United States, 1991\u20132001. MMWR Surveil. Summ. 52, 1\u201324 (2003).","journal-title":"MMWR Surveil. Summ."},{"key":"70996_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/hv.7.0.14613","volume":"7","author":"F Micheletti","year":"2011","unstructured":"Micheletti, F., Moretti, U., Tridente, G. & Zanoni, G. Consultancy and surveillance of post-immunization adverse events in the Veneto region of Italy for 1992\u20132008. Hum. Vaccine 7, 1\u20136 (2011).","journal-title":"Hum. Vaccine"},{"key":"70996_CR24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.puhe.2015.11.010","volume":"135","author":"AM Alguacil-Ramos","year":"2016","unstructured":"Alguacil-Ramos, A. M. et al. Surveillance for adverse events following immunization (AEFI) for 7 years using a computerized vaccination system. Public Health 135, 66\u201374 (2016).","journal-title":"Public Health"},{"key":"70996_CR25","first-page":"853083","volume":"1","author":"MPL Cunha","year":"2013","unstructured":"Cunha, M. P. L., D\u00f3rea, J. G., Marques, R. C. & Le\u00e3o, R. S. Vaccine adverse events reported during the first ten years (1998\u20132008) after introduction in the State of Rondonia, Brazil. Biomed. Res. Int. 1, 853083 (2013).","journal-title":"Biomed. Res. Int."},{"issue":"suppl 1","key":"70996_CR26","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1517\/14740338.2014.939581","volume":"13","author":"C Ferrajolo","year":"2014","unstructured":"Ferrajolo, C. et al. Pediatric drug safety surveillance in Italian pharmacovigilance network: an overview of adverse drug reactions in the years 2001\u20132012. Expert Opin. Drug Saf. 13(suppl 1), S9\u2013S20 (2014).","journal-title":"Expert Opin. Drug Saf."},{"key":"70996_CR27","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.vaccine.2010.12.123","volume":"29","author":"L H\u00e4rmark","year":"2011","unstructured":"H\u00e4rmark, L., van Hunsel, F., Hak, E. & van Grootheest, K. Monitoring the safety of influenza A (H1N1) vaccine using web-based intensive monitoring. Vaccine 29, 1941\u20131947 (2011).","journal-title":"Vaccine"},{"key":"70996_CR28","unstructured":"MedDRA MSSO. Introductory Guide MedDRA Version 23.0. https:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_23_0_english.pdf (2020)"},{"key":"70996_CR29","unstructured":"Eurostat: Population: demography, population projections, census, asylum and migration. https:\/\/ec.europa.eu\/eurostat\/web\/population\/overview (2020)."},{"key":"70996_CR30","unstructured":"EU Directive 2010\/84\/EU of the European Parliament and of the council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001\/83\/EC on the Community code relating to medicinal products for human use on the Community code relating to medicinal products for human use. https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol (2010)."},{"key":"70996_CR31","unstructured":"EMA. Inclusion\/exclusion criteria for the \u201cImportant Medical Events\u201d list. https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Other\/2016\/08\/WC500212100.pdf (2018)."},{"key":"70996_CR32","unstructured":"WHO. Causality Assessment of an Adverse Event Following Immunization (AEFI), User manual for the revised WHO classification (second edition). https:\/\/www.who.int\/vaccine_safety\/publications\/gvs_aefi\/en\/ (2018)."},{"key":"70996_CR33","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1016\/j.vaccine.2013.08.087","volume":"31","author":"AE Tozzi","year":"2013","unstructured":"Tozzi, A. E. et al. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine. 31, 5041\u20135046 (2013).","journal-title":"Vaccine."},{"key":"70996_CR34","unstructured":"EMA. Guidelines on good pharmacovigilance practices (GVP). https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2017\/10\/WC500236404.pdf. (2017)."},{"key":"70996_CR35","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00228-008-0475-9","volume":"64","author":"L H\u00e4rmark","year":"2008","unstructured":"H\u00e4rmark, L. & van Grootheest, A. C. Pharmacovigilance: methods, recent developments and future perspectives. Eur. J. Clin. Pharmacol. 64, 743\u2013752 (2008).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"70996_CR36","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/bcp.13841","volume":"85","author":"G Bonaldo","year":"2019","unstructured":"Bonaldo, G., Vaccheri, A., D\u2019Annibali, O. & Motola, D. Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017. Br. J. Clin. Pharmacol. 85, 634\u2013643 (2019).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"70996_CR37","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell, L. & Shakir, S. A. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 29, 385\u2013396 (2006).","journal-title":"Drug Saf."},{"key":"70996_CR38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14740338.2019.1559812","volume":"18","author":"R Niu","year":"2019","unstructured":"Niu, R. et al. The quality of spontaneous adverse drug reaction reports from the pharmacovigilance centre in western China. Expert Opin. Drug Saf. 18, 51\u201358 (2019).","journal-title":"Expert Opin. Drug Saf."},{"key":"70996_CR39","first-page":"828","volume":"82","author":"KS Lankinen","year":"2004","unstructured":"Lankinen, K. S. et al. Vaccinovigilance in Europe\u2014need for timeliness, standardization and resources. Bull. World Health Organ. 82, 828\u2013835 (2004).","journal-title":"Bull. World Health Organ."},{"key":"70996_CR40","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.vaccine.2018.02.012","volume":"36","author":"J Lei","year":"2018","unstructured":"Lei, J., Balakrishnan, M. R., Gidudu, J. F. & Zuber, P. L. F. Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000\u20132015. Vaccine 36, 1577\u20131582 (2018).","journal-title":"Vaccine"},{"key":"70996_CR41","first-page":"1","volume":"44","author":"A Dey","year":"2020","unstructured":"Dey, A. et al. Surveillance of adverse events following immunisation in Australia: annual report, 2018. Commun. Dis. Intell. 44, 1\u201328 (2020).","journal-title":"Commun. Dis. Intell."},{"key":"70996_CR42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","volume":"37","author":"T Bergvall","year":"2014","unstructured":"Bergvall, T., Nore, G. N. & Lindquist, M. VigiGrade: a tool to identify well-documented Individual case reports and highlight systematic data quality issues. Drug Saf. 37, 65\u201377 (2014).","journal-title":"Drug Saf."},{"key":"70996_CR43","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4161\/hv.7.0.14576","volume":"7","author":"R Gasparini","year":"2011","unstructured":"Gasparini, R. et al. Safety and tolerability of bivalent HPV vaccine: an Italian post-licensure study. Hum. Vaccin. 7, 136\u2013146 (2011).","journal-title":"Hum. Vaccin."},{"key":"70996_CR44","first-page":"262","volume":"104","author":"S Spila-Alegiani","year":"2013","unstructured":"Spila-Alegiani, S., Da Cas, R., Giambi, C., Raschetti, R. & Salmaso, S. Il registro del vaccino anti HPV. [The register of anti HPV vaccine]. Recent Prog. Med. 104, 262\u2013266 (2013).","journal-title":"Recent Prog. Med."},{"key":"70996_CR45","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/21645515.2015.1101198","volume":"12","author":"S Cocchio","year":"2016","unstructured":"Cocchio, S. et al. A postmarket safety comparison of 2 vaccination strategies for measles, mumps, rubella and varicella in Italy. Hum. Vaccin. Immunother. 12, 651\u2013654 (2016).","journal-title":"Hum. Vaccin. Immunother."},{"key":"70996_CR46","unstructured":"AIFA. Rapporto sulla sorveglianza postmarketing dei vaccini in Italia 2017. [Report of vaccine postmarketing surveillance in Italy 2017]. https:\/\/www.agenziafarmaco.gov.it\/content\/rapporto-vaccini-2017-sorveglianza-postmarketing-italia (2018)."},{"key":"70996_CR47","unstructured":"Piano Nazionale Prevenzione Vaccinale 2017\u201319 [National prevention plan 2017\u201319]. https:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_2571_allegato.pdf (2017)."},{"key":"70996_CR48","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/1471-2458-11-329","volume":"11","author":"SL Deeks","year":"2011","unstructured":"Deeks, S. L. et al. Estimating background rates of Guillain\u2013Barr\u00e9 Syndrome in Ontario in order to respond to safety concerns during pandemic H1N1\/09 immunization campaign. BMC Public Health 11, 329 (2011).","journal-title":"BMC Public Health"},{"key":"70996_CR49","doi-asserted-by":"crossref","first-page":"e71818","DOI":"10.1371\/journal.pone.0071818","volume":"8","author":"Y Wang","year":"2013","unstructured":"Wang, Y. et al. The expected number of background disease events during mass immunization in China. PLoS ONE 8, e71818 (2013).","journal-title":"PLoS ONE"},{"key":"70996_CR50","doi-asserted-by":"crossref","unstructured":"Alfonsi V, et al. Regional coordinators for infectious diseases and vaccinations. Immunisation registers in Italy: a patchwork of computerisation. Euro Surveill. https:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=20156 (2012).","DOI":"10.2807\/ese.17.17.20156-en"},{"key":"70996_CR51","first-page":"77","volume":"30","author":"F D'Ancona","year":"2018","unstructured":"D\u2019Ancona, F., Gianfredi, V., Riccardo, F. & Iannazzo, S. Immunisation Registries at regional level in Italy and the roadmap for a future Italian National Registry. Ann. Ig. 30, 77\u201385 (2018).","journal-title":"Ann. Ig."},{"key":"70996_CR52","doi-asserted-by":"crossref","unstructured":"Hazell L, et al. On behalf of the yellow card study collaboration. how do patients contribute to signal detection? a retrospective analysis of spontaneous reporting of adverse drug reactions in the UK\u2019s yellow card scheme. Drug Saf. 36, 199\u2013206 (2013).","DOI":"10.1007\/s40264-013-0021-2"},{"key":"70996_CR53","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bcp.13098","volume":"83","author":"P In\u00e1cio","year":"2017","unstructured":"In\u00e1cio, P., Cavaco, A. & Airaksinen, M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J. Clin. Pharmacol. 83, 227\u2013246 (2017).","journal-title":"Br J. Clin. Pharmacol."},{"key":"70996_CR54","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40264-016-0441-x","volume":"39","author":"L H\u00e4rmark","year":"2016","unstructured":"H\u00e4rmark, L. et al. A patient-reported safety information: a renaissance of pharmacovigilance?. Drug Saf. 39, 883\u2013890 (2016).","journal-title":"Drug Saf."},{"key":"70996_CR55","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4161\/hv.34360","volume":"11","author":"C Alicino","year":"2015","unstructured":"Alicino, C. et al. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety. The two-years\u2019 experience of the Liguria Region, Italy. Hum. Vaccin. Immunother. 11, 91\u201394 (2015).","journal-title":"Hum. Vaccin. Immunother."},{"key":"70996_CR56","doi-asserted-by":"crossref","first-page":"206","DOI":"10.14745\/ccdr.v44i09a04","volume":"44","author":"N Ahmadipour","year":"2018","unstructured":"Ahmadipour, N. et al. Vaccine safety surveillance in Canada: Reports to CAEFISS, 2013\u20132016. Can. Commun. Dis. Rep. 44, 206\u2013214 (2018).","journal-title":"Can. Commun. Dis. Rep."},{"key":"70996_CR57","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4067\/S0716-10182019000400461","volume":"36","author":"PO Thomsen","year":"2019","unstructured":"Thomsen, P. O., Salda\u00f1a, V. A., Cerda, L. J. & Abarca, V. K. Vaccine safety: description of the adverse events reported to the surveillance system in Chile, 2014 to 2016. Rev. Chilena Infectol. 36, 461\u2013468 (2019).","journal-title":"Rev. Chilena Infectol."},{"key":"70996_CR58","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","volume":"33","author":"TT Shimabukuro","year":"2015","unstructured":"Shimabukuro, T. T., Nguyen, M., Martin, D. & DeStefano, F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 33, 4398\u20134405 (2015).","journal-title":"Vaccine."},{"key":"70996_CR59","unstructured":"CDC Vaccine Safety. Common concerns: childhood vaccines and febrile seizures. https:\/\/www.cdc.gov\/vaccinesafety\/concerns\/febrile-seizures.html (2016)."},{"key":"70996_CR60","unstructured":"AIFA. AIFA dispone il divieto di utilizzo per due lotti del vaccino antinfluenzale FLUAD 27\/11\/2014 [AIFA disposal on a ban on the use of two batches of FLUAD flu vaccine 11\/27\/2014]. https:\/\/www.agenziafarmaco.gov.it\/content\/aifa-dispone-il-divieto-di-utilizzo-due-lotti-del-vaccino-antinfluenzale-fluad-0 (2014)."},{"key":"70996_CR61","unstructured":"AIFA. Comunicato AIFA per gli operatori sanitari: Aggiornamento sul rischio di febbre e convulsioni febbrili dopo somministrazione della prima dose di vaccino tetravalente morbillo, parotite, rosolia e varicella [AIFA release for health professionals: Update on the risk of fever and febrile convulsions after administration of the first dose of tetravalent measles, mumps, rubella and varicella vaccine]. https:\/\/www.aifa.gov.it\/sites\/default\/files\/comunicato_AIFA_MPRV.pdf (2013)."},{"key":"70996_CR62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2807\/1560-7917.ES2015.20.7.21041","volume":"20","author":"F Trotta","year":"2015","unstructured":"Trotta, F., Rizzo, C., Santuccio, C. & Bella, A. the Pharmacovigilance Study Group on Pneumococcal Comparative safety evaluation of 7-valent and 13-valent pneumococcal vaccines in routine paediatric vaccinations in four Italian regions, 2009 to 2011. Euro Surveill. 20, 21\u201328 (2015).","journal-title":"Euro Surveill."},{"key":"70996_CR63","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000438752","volume":"45","author":"MD Benedetti","year":"2015","unstructured":"Benedetti, M. D. et al. A multicentric prospective incidence study of Guillain\u2013Barr\u00e9 syndrome in Italy. The ITANG study. Neuroepidemiology 45, 90\u201399 (2015).","journal-title":"Neuroepidemiology"},{"key":"70996_CR64","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10654-013-9797-8","volume":"28","author":"F Galeotti","year":"2013","unstructured":"Galeotti, F. et al. Risk of Guillain\u2013Barr\u00e9 syndrome after 2010\u20132011 influenza vaccination. Eur. J. Epidemiol. 28, 433\u2013444 (2013).","journal-title":"Eur. J. Epidemiol."},{"key":"70996_CR65","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13052-016-0298-8","volume":"42","author":"F Trotta","year":"2016","unstructured":"Trotta, F., Da Cas, R., Bella, A., Santuccio, C. & Salmaso, S. Intussusception hospitalizations incidence in the pediatric population in Italy: a nationwide cross-sectional study. Ital. J. Pediatr. 42, 89 (2016).","journal-title":"Ital. J. Pediatr."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70996-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70996-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70996-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T17:41:53Z","timestamp":1670348513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70996-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,24]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["70996"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-70996-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,24]]},"assertion":[{"value":"21 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14122"}}